

1 **Comparison of the accuracy of the 7-item HADS Depression subscale and 14-item total**
2 **HADS for screening for major depression: a systematic review and individual participant**
3 **data meta-analysis**

4
5 **Abstract**

6 The 7-item Hospital Anxiety and Depression Scale Depression subscale (HADS-D) and
7 the total score of the 14-item HADS (HADS-T) are both used for major depression screening.
8 Compared to the HADS-D, the HADS-T includes anxiety items and requires more time to
9 complete. We compared the screening accuracy of the HADS-D and HADS-T for major
10 depression detection. We conducted an individual participant data meta-analysis and fit bivariate
11 random-effects models to assess diagnostic accuracy among participants with both HADS-D and
12 HADS-T scores. We identified optimal cutoffs, estimated sensitivity and specificity with 95%
13 confidence intervals (CIs), and compared screening accuracy across paired cutoffs via two-stage
14 and individual-level models. We used a 0.05 equivalence margin to assess equivalency in
15 sensitivity and specificity. 20,700 participants (2,285 major depression cases) from 98 studies
16 were included. Cutoffs of ≥ 7 for the HADS-D (sensitivity 0.79 [0.75, 0.83], specificity 0.78
17 [0.75, 0.80]) and ≥ 15 for the HADS-T (sensitivity 0.79 [0.76, 0.82], specificity 0.81 [0.78,
18 0.83]) minimized the distance to the top-left corner of the receiver operating characteristic curve.
19 Across all sets of paired cutoffs evaluated, differences of sensitivity between HADS-T and
20 HADS-D ranged from -0.05 to 0.01 (0.00 at paired optimal cutoffs), and differences of
21 specificity were within 0.03 for all cutoffs (0.02 to 0.03). The pattern was similar among
22 outpatients, although the HADS-T was slightly (not non-equivalently) more specific among

23 inpatients. The accuracy of HADS-T was equivalent to the HADS-D for detecting major
24 depression. In most settings, the shorter HADS-D would be preferred.

25 **Keywords:** HADS-D, HADS-T, individual participant data meta-analysis, depression
26 screening, diagnostic accuracy

27 **Public significance statements:**

28 The present study suggests that the accuracy of 14-item Hospital Anxiety and Depression Scale
29 (HADS-D) and the 7-item HADS Depression subscale (HADS-D) are equivalent for detecting
30 major depression. Using the 7-item HADS-D for depression screening instead of the full 14-item
31 HADS-T has minimal influence on performance of the measure but would reduce patient and
32 participant burden in most clinical and research settings.

33

34 The 14-item Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983)
35 was developed to facilitate the identification of anxiety disorders and major depression in people
36 with a physical illness. The HADS includes two subscales. The 7-item Depression subscale
37 (HADS-D) was designed to assess continuous depressive symptoms and for depression
38 screening, whereas the 7-item Anxiety subscale (HADS-A) was designed to assess and screen for
39 anxiety (Zigmond & Snaith, 1983). Both HADS-D and full HADS total scores (HADS-T) have
40 been used to screen for major depression (Mitchell, Meader, & Symonds, 2010; Vodermaier &
41 Millman, 2011). The HADS-T takes more time to complete and includes anxiety items not
42 specific to depression. Some have suggested, though, that anxiety symptoms should be
43 considered when assessing depression (Schatzberg, 2019). Furthermore, previous reviews have
44 provided some preliminary evidence that HADS-T may perform better than the HADS-D
45 (Mitchell, Meader, & Symonds, 2010; Vodermaier & Millman, 2011).

46 Commonly used HADS-D cutoff thresholds of ≥ 8 for “possible” depression and ≥ 11 for
47 “probable” depression were established in the original validation study, which included only 100
48 participants (11 depression cases) (Zigmond & Snaith, 1983). A recent individual participant
49 data meta-analysis (IPDMA) on HADS-D accuracy to screen for major depression (101 studies;
50 22,574 participants; 2,549 major depression cases) found that a cutoff of ≥ 7 maximized
51 combined sensitivity and specificity across reference standards; standard cutoffs of ≥ 8 and ≥ 11
52 were less sensitive but more specific (Wu, Levis, Sun, et al., 2021). There is not a standard cutoff
53 for screening to detect major depression with the HADS-T.

54 Two previous meta-analyses, both done with studies of cancer patients, have indirectly
55 compared the HADS-D and HADS-T for detecting major depression (Mitchell et al., 2010;
56 Vodermaier & Millman, 2011). Both searched through October 2009 for eligible studies. One

57 evaluated 9 studies that used the HADS-D with a cutoff of 8 or greater and 6 studies that used
58 the HADS-T with a cutoff of 15 (number of participants not reported) (Mitchell et al., 2010),
59 whereas the other included 2-5 studies each in analyses of HADS-D cutoffs of 7, 9, and 11 and
60 HADS-T cutoffs of 15, 17, 19 and 20 (470 to 872 participants per analysis) (Vodermaier &
61 Millman, 2011). Both meta-analyses suggested that the HADS-T may perform better than the
62 HADS-D, but there was a high level of uncertainty due to indirect comparisons between
63 participants from different studies that reported HADS-D and HADS-T results, the small number
64 of total participants, and possible selective outcome reporting bias (Levis et al., 2017; Neupane
65 et al., 2021; Rice & Thombs, 2016; Thombs et al., 2011; Thombs & Rice, 2016) since not all
66 primary studies reported results from the same cutoffs.

67 Using the full 14-item HADS-T for depression screening would be warranted if it is
68 sufficiently more accurate than the shorter 7-item HADS-D to justify the additional time and
69 patient burden involved. We previously assessed the accuracy of the HADS-D using IPDMA
70 (Wu, Levis, Sun, et al., 2021). IPDMA involves a standard systematic review, followed by
71 synthesis of original research data from primary studies, rather than extracting summary data
72 (Riley, Lambert, & Abo-Zaid, 2010). In that IPDMA, we found that diagnostic accuracy of
73 HADS-D was not significantly different for any cutoffs across reference standards based on
74 participant characteristics, including age, sex, cancer diagnosis, country human development
75 index levels, participant recruitment settings, or the study's risk of bias ratings (Wu et al., 2021).
76 In the present study, we included studies from the HADS-D IPDMA where HADS-T scores were
77 provided or could be calculated from individual item scores. Our objectives were to (1) directly
78 compare screening accuracy of the HADS-T and HADS-D for major depression detection using
79 the same participant data across all studies regardless of reference standard, and (2) replicate the

80 comparison among studies that used a semi-structured diagnostic interview [e.g., Structured
81 Clinical Interview for the DSM (SCID) (First, 1995)] as a reference standard, since semi-
82 structured interviews more closely reflect the actual diagnostic process than fully-structured
83 interviews.

84 **Methods**

85 The present study used a subset of studies and participants from our previously conducted
86 HADS-D IPDMA (Wu, Levis, Sun, et al., 2021) for which HADS-T scores were also available.
87 Analyses of HADS-D and HADS-T diagnostic accuracy were conducted according to the
88 HADS-D IPDMA methods (Wu, Levis, Sun, et al., 2021) with the addition of analyses to
89 directly compare HADS-D and HADS-T accuracy.

90 **Dataset eligibility**

91 For the main HADS-D meta-analysis, datasets from articles in any language were eligible
92 for inclusion if (1) they included diagnostic classification for current Major Depressive Disorder
93 (MDD) or Major Depressive Episode (MDE) using Diagnostic and Statistical Manual of Mental
94 Disorders (DSM) (American Psychiatric Association, 1987; 1994; 2000; 2013) or International
95 Classification of Diseases (ICD) (World Health Organization (WHO), 1992) criteria based on a
96 validated semi-structured or fully structured interview; (2) they included total scores for the
97 HADS-D; (3) the diagnostic interview and HADS-D were administered within two weeks of
98 each other, because DSM and ICD major depression diagnostic criteria specify that symptoms
99 must have been present in the last two weeks; (4) participants were ≥ 18 years of age and not
100 recruited from youth or psychiatric settings; and (5) participants were not recruited because they
101 were identified as having symptoms of depression, since screening is done to identify previously
102 unrecognized cases. We focused on MDD and MDE because major guidelines on depression

103 screening have focused on screening for major depression but have not considered screening for
104 less severe conditions, such as dysthymia or persistent depressive disorder, for which treatment
105 options and effectiveness are much less well delineated (Joffres et al., 2013; National
106 Collaborating Centre for Mental Health (UK), 2010; Siu & US Preventive Services Task Force,
107 2016). Consistent with this, few primary studies collect or report diagnostic status for dysthymia
108 or persistent depressive disorder. Datasets where not all participants were eligible were included
109 if primary data allowed selection of eligible participants. For the present study, we only included
110 primary datasets from the HADS-D IPDMA that also provided HADS-T scores or item scores to
111 calculate HADS-T scores.

112 **Search strategy and study selection**

113 A medical librarian searched Medline, Medline In-Process & Other Non-Indexed Citations
114 and PsycINFO via OvidSP, and Web of Science via ISI Web of Knowledge from inception to
115 October 25, 2018 using a peer-reviewed (McGowan, Sampson, Salzwedel, Cogo, Foerster, &
116 Lefebvre, 2016) search strategy (Supplementary Methods A). We also reviewed reference lists of
117 relevant reviews and queried contributing authors about non-published studies. Search results
118 were uploaded into RefWorks (RefWorks-COS, Bethesda, MD, USA). After de-duplication,
119 unique citations were uploaded into DistillerSR (Evidence Partners, Ottawa, Canada) for
120 tracking search results.

121 Pairs of investigators independently reviewed titles and abstracts for eligibility. If either
122 deemed a study potentially eligible, full-text review was done by two investigators,
123 independently, with disagreements resolved by consensus, consulting a third investigator when
124 necessary. Translators were consulted for languages other than those for which team members
125 were fluent.

126 **Data contribution, extraction, and synthesis**

127 Authors of eligible datasets were invited to contribute de-identified primary data. We
128 emailed corresponding authors of eligible primary studies at least three times, as necessary. If we
129 did not receive a response, we emailed co-authors and attempted to contact corresponding
130 authors by phone.

131 Diagnostic interview and country were extracted from published reports by pairs of
132 investigators independently, with disagreements resolved by consensus. Countries were
133 categorized as “very high”, “high” or “low-medium” development based on the United Nation’s
134 Human Development Index (HDI) for the country for the year of the study publication. The HDI
135 is a statistical composite index that includes indicators of life expectancy, education, and income
136 (United Nations Development Programme, 2020). Participant-level data included age, sex,
137 participant recruiting setting, HADS-D scores, HADS-T scores, and major depression status
138 (case or non-case). For defining major depression, we considered MDD or MDE based on the
139 DSM or ICD. If more than one was reported, we prioritized MDE over MDD (because screening
140 would attempt to detect depressive episodes and further interview would determine if the episode
141 is related to MDD, bipolar disorder or persistent depressive disorder). We also prioritized DSM
142 over ICD because most studies use DSM criteria.

143 Individual participant data were converted to a standard format and synthesized into a
144 single dataset with study-level data. We compared published participant characteristics and
145 diagnostic accuracy estimates with results from raw datasets and resolved any discrepancies in
146 consultation with primary study investigators.

147 **Risk of Bias Assessment**

148 Risk of bias of included studies was assessed by two investigators independently using
149 the QUality Assessment of Diagnostic Accuracy Studies-2 tool (QUADAS-2; Supplementary
150 Methods B) (Whiting et al., 2011). Any discrepancies were resolved via consensus with a third
151 investigator involved as necessary. Risk of bias was coded at both study and participant levels
152 since some classifications (e.g., the time between index test and reference standard) may have
153 differed among participants from the same study. The QUADAS-2 results were used to describe
154 the risk of bias of each included study.

155 **Statistical Analyses**

156 To compare the screening accuracy of the HADS-D and HADS-T across relevant cutoffs to
157 detect major depression, we first estimated overall sensitivity and specificity for HADS-D and
158 HADS-T by combining all studies regardless of reference standard. Reference standards used in
159 primary studies included semi-structured interviews (e.g., SCID (First, 1995)), fully structured
160 interviews (the Mini International Neuropsychiatric Interview (MINI) excluded) (e.g., Composite
161 International Diagnostic Interview (CIDI) (Robins et al., 1988)), and the MINI (Lecrubier et al.,
162 1997; Sheehan et al., 1997). Different types of reference standards have different design and
163 performance characteristics (Levis, Benedetti, et al., 2019; Levis et al., 2020; Wu, Levis,
164 Ioannidis, et al., 2021; Wu, Levis, Sun, et al., 2020), and estimates of sensitivity and specificity
165 differ by type (Negeri, et al., 2021; Levis, Benedetti, et al., 2019; Levis et al., 2020; Wu, Levis,
166 Sun, et al., 2021). It is reasonable to assume, though, that differences in sensitivity and
167 specificity between HADS-D and HADS-T accuracy among the same participants are not
168 associated with reference standard type, since in each primary study the HADS-D and HADS-T
169 were compared to the same reference standard. Thus, our main analysis included all studies
170 regardless of reference standard.

171 Separately, as a sensitivity analysis, to ensure that results would not differ by clinical
172 interview, we repeated all analyses for only studies that used a semi-structured interview as the
173 reference standard. Semi-structured interviews (e.g., SCID (First, 1995), Schedules for Clinical
174 Assessment in Neuropsychiatry (WHO, 1994), Schedule for Affective Disorders and
175 Schizophrenia (Endicott & Spitzer, 1987), and Monash Interview for Liaison Psychiatry (Clarke,
176 Smith, Herrman, & McKenzie, 1998)) are intended to be administered by experienced
177 diagnosticians and are considered to more closely reflect clinical diagnostic procedures than fully
178 structured interviews or the MINI (Brugha, Bebbington, & Jenkins, 1999; Brugha, Jenkins, Taub,
179 Meltzer, & Bebbington, 2001; Nosen & Woody, 2008). We did not conduct additional sensitivity
180 analyses with fully structured interviews or the MINI.

181 Overall and separately, for studies that used a semi-structured reference standard, for all
182 possible cutoffs 0-21 of the HADS-D and 0-42 of the HADS-T, we fitted bivariate random-
183 effects models via Gauss-Hermite quadrature (Riley, Dodd, Craig, Thompson, & Williamson,
184 2008). This is a two-stage meta-analytic approach that models sensitivity and specificity
185 simultaneously and accounts for the correlation between them and the precision of estimates
186 within studies. We also constructed empirical receiver operating characteristic (ROC) plots based
187 on pooled sensitivity and specificity estimates and calculated area under the curves (AUC) for
188 the two tests.

189 To investigate heterogeneity across studies, overall and for studies with a semi-structured
190 reference standard, we generated forest plots for the differences in sensitivity and specificity
191 estimates between the HADS-D and HADS-T for the optimal cutoffs based on pooled results.
192 We also quantified heterogeneity at the optimal cutoffs for the HADS-D and HADS-T by
193 reporting the estimated variances of the random effects for the differences in the HADS-D and

194 HADS-T sensitivity and specificity (τ^2) (Fagerland, Lydersen, & Laake, 2014; Higgins &
195 Thompson, 2002).

196 To compare the diagnostic accuracy of the HADS-D and HADS-T, using the analyses
197 that pooled across reference standards and within semi-structured reference standard category,
198 we first calculated the differences of the AUCs with 95% confidence intervals (CIs). Second, we
199 compared the ROC plots visually to determine if one measure consistently perform better than
200 the other across cutoffs. Third, we compared differences in sensitivity and specificity for optimal
201 cutoffs and other cutoffs close to the optimal cutoff to determine if there were differences and the
202 magnitude of any differences. To do this, we identified the optimal cutoff that minimized the
203 values of the distance to the top-left corner of the ROC curves (NCSS, 2017) for both HADS-D
204 and HADS-T and a set of other cutoffs that were close to the optimal cutoff. The distance to the
205 top-left corner of the ROC curve for each cutoff value is calculated by $d =$

206 $\sqrt{(1-\text{Sensitivity})^2+(1-\text{Specificity})^2}$ (NCSS, 2017). Since there is no *a priori* method to align
207 cutoffs on the HADS-D and HADS-T that perform most similarly in terms of sensitivity and
208 specificity, we did this based on examination of results and consensus among investigators.

209 Then, we compared the sensitivity and specificity between the HADS-D and HADS-T for pairs
210 of optimal cutoffs and four other pairs of cutoffs close to the optimal; the interval between
211 cutoffs for HADS-T was 2 instead of 1 because HADS-T doubled the length and the total score
212 of HADS-D. For all cutoffs on the HADS-D and HADS-T, 95% CIs for the differences between
213 HADS-D and HADS-T sensitivity and specificity were constructed via a cluster bootstrap
214 approach (Van der Leeden, Busing, & Meijer, 1997; Van der Leeden, Meijer, & Busing, 2008)
215 with resampling at the study and subject level. For each comparison, we ran 1000 iterations of
216 the bootstrap. For each bootstrap iteration, the bivariate random-effects model was fitted to the

217 HADS-D and HADS-T data, and the pooled sensitivities and specificities were computed
218 separately, as described above, for all cutoffs of HADS-D and HADS-T.

219 In addition to comparing the HADS-D and HADS-T with pooling of study-level results,
220 as a sensitivity analysis, we compared sensitivity and specificity of the HADS-D and HADS-T
221 across cutoffs via an individual-level analysis. For the individual-level analysis, for each pair of
222 matched HADS-D and HADS-T cutoffs, we fitted a linear mixed model with the difference
223 between the HADS-D and HADS-T screening results as the outcome. The screening result is
224 dichotomous, either positive = 1 or negative = 0. If the HADS-T screening result was positive
225 (which was 1), but HADS-D was negative (which was 0), the outcome, i.e., the difference
226 between HADS-T and HADS-D results, was $1 - 0 = 1$; if both screening results were positive or
227 negative, the outcome was 0 ($1 - 1$ or $0 - 0$); and if the HADS-T screening result was negative,
228 but HADS-D was positive, the outcome was -1 ($0 - 1 = -1$). This model modeled the differences
229 in sensitivity and specificity simultaneously and included random effects both at the study level.
230 From this model, for each set of HADS-D and HADS-T paired cutoffs, we estimated the
231 difference in sensitivity and specificity between the two tests and associated CIs. These CIs from
232 the bootstrap approach and individual-level analysis allowed us to test whether the sensitivity
233 and specificity of the HADS-T is equivalent to that of the HADS-D based on a pre-specified
234 equivalence margin of $\delta = 0.05$ (Walker & Nowacki, 2011), as we have done in previous studies
235 (Harel et al., 2021; Ishihara et al., 2019; Wu, Levis, Riehm, et al., 2020).

236 As a sensitivity analysis, we compared accuracy of HADS-D and HADS-T results
237 stratified by subgroups based on inpatient and outpatient care settings (we planned to conduct
238 sensitivity analysis in each participant recruit setting, separately, but we were able to do this only
239 for inpatient and outpatient medical settings because there were too few participants from non-

240 medical and mixed inpatient/outpatient settings). In addition, we conducted a subgroup analysis
241 only among patients from cancer studies because meta-analyses (Mitchell et al., 2010;
242 Vodermaier & Millman, 2011) of studies from cancer care settings reported that the HADS-T
243 may perform better than the HADS-D in those settings. We did not conduct the sensitivity
244 analysis to assess whether inclusion of published results from the eligible studies that did not
245 provide raw data influenced results because we did this in the main HADS-D IPDMA and found
246 no differences (Wu et al., 2021).

247 To examine whether measurement differences across participant characteristics,
248 including country, may have influenced our results, we assessed whether sensitivity and
249 specificity differed for the HADS-D based on these characteristics, and then, we re-examined
250 HADS-D and HADS-T differences for any variables where differences were found. To assess
251 possible influences on sensitivity and specificity, we conducted one-stage meta-regressions. In
252 the first step, we repeated the analysis that we did in the main HADS-D IPDMA by interacting
253 all subgrouping variables (age [measured continuously], sex [reference category = female]),
254 country HDI level [reference category = very high], cancer diagnosis [reference category = no],
255 participant recruiting setting [reference category = inpatient specialty care], interactions of
256 QUADAS-2 signaling item responses [reference category = low risk] with logit (sensitivity) and
257 logit (1 – specificity) of the HADS-D (Wu et al., 2021). We conducted these analyses separately
258 by reference standards (semi-structured interview, fully structured interview, MINI), since these
259 types of interviews have been shown to identify different individuals (Wu et al., 2021). In the
260 second step, we added country/language variables to the model (Germany, Spain, Lithuania,
261 Norway, Korea, Japan [reference category = English speaking countries]). These models were
262 restricted to the subset of the studies from countries with more than 500 participants that had

263 complete data for all relevant variables and used a semi-structured interview or the MINI (there
264 were not enough data for the studies that used a fully structured reference standard). Country
265 HDI level was dropped from the model because all countries included in this analysis had very
266 high HDI. For any variables that were found to be associated with the sensitivity or specificity
267 across all cutoffs, we compared accuracy of HADS-D and HADS-T results stratified by
268 subgroups based on these variables.

269 All analyses were run in R (R version R 3.5.0 (R Core Team, 2020) and R Studio
270 version 1.1.423 (RStudio Team, 2020)) using the lme4 package (Bates, Maechler, Bolker, &
271 Walker, 2015).

272 **Registration and Protocol**

273 The main HADS-D IPDMA was registered in PROSPERO (CRD42015016761), and a
274 protocol was published (Thombs et al., 2016). The present study was not included in the protocol
275 for the main HADS-D IPDMA, but a separate protocol was developed and posted online prior to
276 initiating the study (<https://osf.io/438ak/>).

277 **Data Availability**

278 Data contribution agreements with primary study authors do not include permission to
279 make their data publicly available, although the dataset used in this study will be archived
280 through a McGill University repository (Borealis,
281 <https://borealisdata.ca/dataverse/depressdproject/>). The R codes used for the analysis will be
282 made publicly available through the same repository. Requests to access the dataset to verify
283 study results but not for other purposes can be sent to the corresponding authors via the “Access
284 Dataset” function on the repository website.

285 **Results**

286 **Search Results and Inclusion of Primary Data**

287 For the main HADS-D IPDMA, of 14,465 unique titles and abstracts identified from the
288 database search, 13,895 were excluded after title and abstract review and 330 after full-text
289 (Supplementary Table A), leaving 240 eligible articles with data from 165 unique participant
290 samples (Supplementary Figure A). Of the 165 unique samples, 93 (56%) contributed data (66%
291 of eligible participants). In addition, authors of included studies contributed data from 10 studies
292 that were unpublished or did not come up in the search, for a total of 103 HADS-D datasets
293 contributed to our IPDMA. Five studies without HADS individual item scores or separate total
294 scores for the HADS-D and HADS-T were excluded from the present study (see Supplementary
295 Table B2). Thus, 20,700 participants (2,285 major depression cases) from 98 studies were
296 analyzed (91% of 22,755 participants from the 103 HADS-D datasets). Included study
297 characteristics are shown in Supplementary Table B1. Characteristics of eligible studies that did
298 not provide data, including the five studies excluded because they only provided HADS-D or
299 HADS-T total scores, are shown in Supplementary Table B2.

300 Of 98 included studies, 58 used semi-structured interviews to assess major depression
301 (10,311 participants), including 54 that used the SCID (9,676 participants); 31 used the MINI
302 (7,445 participants); and 9 used other. Participant characteristics are shown in Table 1.

303 Supplementary Table C shows QUADAS-2 ratings for included studies. There were only
304 11 studies with “low” risk of bias rating across all QUADAS-2 domains.

305 **Comparison of Screening Accuracy Between the HADS-D and HADS-T**

306 ROC plots comparing sensitivity and specificity estimates for all cutoffs between the
307 HADS-D (0-21) and HADS-T (0-42) among all included studies are shown in Figure 1. A large
308 part of the plots for the HADS-D and HADS-T were overlapping. The HADS-T performed better

309 than HADS-D at some cutoffs, but this pattern was not consistent across cutoffs. The AUCs for
310 the HADS-D and HADS-T were similar among all studies (0.853 versus 0.872). We also
311 compared the ROCs among studies that used a semi-structured reference standard and found a
312 similar pattern (Supplementary Figure B).

313 Based on the pooled sensitivity and specificity across all HADS-D and HADS-T cutoffs,
314 among all studies, the cutoff that minimized the values of the distance to the top-left corner of
315 the ROC curves was ≥ 7 for the HADS-D (sensitivity [95% CI] = 0.79 [0.75, 0.83], specificity
316 [95% CI] = 0.78 [0.75, 0.80]) and ≥ 15 for the HADS-T (sensitivity [95% CI] = 0.79 [0.76,
317 0.82], specificity [95% CI] = 0.81 [0.78, 0.83]) (Table 2).

318 The comparison of sensitivity and specificity between the HADS-D and HADS-T for the
319 optimal cutoffs (HADS-D ≥ 7 vs. HADS-T ≥ 15) and other cutoffs close to the optimal cutoffs (\geq
320 5 vs. ≥ 11 ; ≥ 6 vs. ≥ 13 ; ≥ 8 vs. ≥ 17 ; ≥ 9 vs. ≥ 19 ; ≥ 10 vs. ≥ 21 ; and ≥ 11 vs. ≥ 23 are presented
321 in Table 2. Overall, for the pairs of optimal cutoffs or other cutoffs close to the optimal, the
322 differences in sensitivity and specificity between HADS-D and HADS-T using the bootstrapping
323 approach across all 98 primary studies were small. Precision of estimates was high, and the
324 width of 95% CIs ranged from 5% to 9% for sensitivity and 2% to 4% for specificity across all
325 cutoffs examined. For sensitivity, the differences of HADS-T – HADS-D for all pairs of cutoffs
326 were not statistically significant (the differences were between -0.05 and 0.01, CIs were within
327 or overlapped with the range of -0.05 and 0.05). Therefore, at five pairs of optimal cutoffs or
328 other cutoffs close to the optimal, the sensitivity of the HADS-T was equivalent to that of the
329 HADS-D; the equivalency was indeterminate on the other two pairs, based on the pre-specified
330 equivalence margin of $\delta = 0.05$. For specificity, estimates of HADS-T were equivalent to HADS-
331 D for all seven pairs of cutoffs (the differences of HADS-T – HADS-D were between 0.02 and

332 0.03; CIs were all within -0.05 and 0.05). Relevant results among studies that used a semi-
333 structured reference standard were consistent with overall estimates (Supplementary Table D1).

334 The comparison of results via individual-level analysis are presented in Table 3. For each
335 pair of matched HADS-D and HADS-T cutoffs, the differences in sensitivity and specificity
336 between the two tests were similar to those from the bivariate random-effects models. This was
337 also true among studies that used a semi-structured reference standard (Supplementary Table
338 D2).

339 Among participants in inpatient care settings (Table 4a; 8,827 participants from 38
340 studies), the comparison results of HADS-T – HADS-D in sensitivity were similar to the overall
341 estimates; the differences in specificity were slightly larger than overall estimates, however, the
342 95% CIs generally overlapped with -0.05 and 0.05 and were classified as indeterminate to
343 equivalency, with one exception (HADS-D \geq 6 vs. HADS-T \geq 13) for which HADS-T specificity
344 was greater than for the HADS-D. The comparison results among participants in outpatient care
345 settings (Table 4b; 9,547 participants from 54 studies) and participants from studies done in
346 cancer care settings (Supplementary Table E; 5608 participants from 23 studies) were similar to
347 overall estimates. Within the semi-structured reference standard category, similar patterns were
348 found (Supplementary Tables D3 and D4).

349 The meta-regression results indicated no significant differences in sensitivity and
350 specificity were found for any individual participant characteristics or risk of bias ratings
351 (Supplementary Table F1-F3). After adding the country/language variables to the model, the
352 sensitivity and specificity of HADS-D was invariant based on all variables across reference
353 standards except that specificity estimates of the HADS-D were associated with Germany and
354 Spain among studies that used a semi-structured reference standard; specifically, the HADS-D

355 had lower specificity among participants from Germany and Spain compared to studies done
356 with participants from English speaking countries (Supplementary Table G1-G2).

357 Therefore, we conducted subgroup analysis of our comparisons of HADS-D and HADS-T
358 accuracy for participants from Germany or Spain. For each pair of matched HADS-D and
359 HADS-T cutoffs among participants from Germany (Supplementary Table H1), the comparison
360 results of HADS-T – HADS-D in sensitivity and specificity were similar to the overall estimates;
361 among participants from Spain (Supplementary Table H2), differences in specificity were
362 slightly larger than overall estimates, however, the 95% CIs all overlapped with -0.05 and 0.05
363 and were classified as indeterminate to equivalent, and differences in sensitivity were similar to
364 the overall estimates.

365 A forest plot of the differences of sensitivity and specificity estimates for HADS-D ≥ 7 vs.
366 HADS-T ≥ 15 across all studies is shown in Figure 2. At the optimal cutoffs, there was low
367 heterogeneity in the differences between HADS-D and HADS-T across the 98 studies with
368 estimated inter-study heterogeneity (τ^2) < 0.01 for sensitivity and < 0.01 for specificity. The
369 forest plot of the differences of sensitivity and specificity estimates at optimal cutoffs for the
370 HADS-D and HADS-T among studies that used a semi-structured reference standard is shown in
371 Supplementary Figure C.

372 Discussion

373 We assessed the equivalency of screening accuracy of the HADS-D and HADS-T across
374 all cutoffs to detect major depression and compared accuracy across paired optimal cutoffs and
375 other cutoffs close to the optimal cutoffs to test whether the HADS-T is superior to HADS-D for
376 major depression detection. There were two main findings. First, among all 98 included studies
377 the values of the distance to the top-left corner of the ROC curves (Riley et al., 2008) were

378 minimized at a HADS-D cutoff ≥ 7 (sensitivity = 0.79, specificity = 0.78) and at a HADS-T
379 cutoff ≥ 15 (sensitivity = 0.79, specificity = 0.81). Second, at paired optimal cutoffs and six other
380 cutoffs close to the optimal cutoffs, the HADS-D was similarly accurate compared to the HADS-
381 T overall and among studies that used a semi-structured reference standard.

382 Overall, for all 98 primary studies, across all sets of paired cutoffs, the sensitivity and
383 specificity of the HADS-T were classified as equivalent to that of the HADS-D based on the pre-
384 specified equivalency margin. Although the HADS-T was slightly more specific (range 0.02 to
385 0.03), all the 95% CIs for differences in sensitivity and specificity of HADS-T – HADS-D were
386 within or overlapped with the range of -0.05 and 0.05. When we analyzed data separately among
387 studies that used a semi-structured reference standard, differences in sensitivity and specificity
388 between the HADS-D and HADS-T were similar to the overall estimates.

389 Furthermore, similar to overall estimates, there were no substantive differences in
390 performance between the HADS-D and HADS-T in detecting major depression among medical
391 outpatients. Among inpatients, the HADS-T and HADS-D were also equivalent in sensitivity.
392 The HADS-T performed slightly better than HADS-D in terms of specificity, and equivalency
393 was indeterminate based on the pre-specified equivalence margin, except for one pair of cutoffs.
394 This finding is possibly related to the greater presence of anxiety symptoms in inpatients versus
395 outpatients and its relationship to depression (Schatzberg, 2019).

396 Previous conventional meta-analyses of results from cancer patients (Mitchell et al.,
397 2010; Vodermaier & Millman, 2011) suggested that the HADS-T may perform better than the
398 HADS-D, but that conclusion was highly uncertain given the limitations of the samples and
399 methods. Through our IPDMA, with its large dataset and more rigorous comparison methods
400 including both bivariate random-effects models and individual-level models, a two-level

401 bootstrap approach (Fagerland et al., 2014; Higgins & Thompson, 2002), and subgroup analysis,
402 we found there was no consistent evidence that the HADS-T is superior to HADS-D for major
403 depression detection, including in cancer care settings. In addition, we did not identify any
404 differences between HADS-D and HADS-T accuracy that were associated with individual
405 participant characteristics or countries. Therefore, in research and clinical general practice, using
406 the full 14-item HADS-T for depression screening would likely result in no to minimal gain in
407 screening accuracy but would add unnecessary burden to patients compared to the 7-item
408 HADS-D.

409 To our knowledge, this is the first meta-analysis that directly compared the HADS-D and
410 HADS-T for screening for depression using the same large individual participant dataset for both
411 screening tools. Strengths of this study included the large overall sample size and high precision
412 of estimates of differences, the ability to compare results for HADS-D and HADS-T across all
413 cutoffs from all studies, and the ability to assess screening accuracy overall and by inpatient and
414 outpatient subgroups. There are also limitations to consider. First, for the full IPDMA data,
415 primary data from 72 of 165 published eligible datasets (44% of datasets, 34% of participants)
416 were not included, and only those datasets with complete data for all individual HADS item
417 scores (91% of available data) were included in this study. Nonetheless, this sample was much
418 larger than the few primary studies that have previously compared the HADS-D and HADS-T.
419 Second, we did not conduct analyses restricted to studies with “low” risk of bias ratings across
420 QUADAS-2 domains. However, in sensitivity analysis in this study and in our main IPDMA on
421 the HADS-D (Wu, et al., 2021), risk of bias ratings were not associated with screening accuracy.
422 Third, the present study used a subset of studies and participants from our previously conducted
423 HADS-D IPDMA (Wu, et al., 2021). This IPDMA project was designed to assess the accuracy

424 of the HADS-D for detecting major depression. Diagnoses of other mental disorders, including,
425 anxiety disorders, were not collected in most of the included primary studies. Thus, we were not
426 able to evaluate the sensitivity and specificity of the HADS-D, HADS-Anxiety, or HADS-T for
427 detecting mental disorders generally. Forth, we did not record inter-rated reliability for risk of
428 bias ratings; however, all ratings were done by trained reviewers and any disagreements were
429 addressed by consensus, including a third investigator as necessary.

430 **Conclusions**

431 In summary, this study found that sensitivity and specificity of the HADS-T were not
432 superior to the HADS-D for detecting major depression in a large individual participant dataset.
433 Using the 7-item HADS-D for depression screening instead of the full 14-item HADS-T has
434 minimal influence on performance of the measure but would reduce patient and participant
435 burden in clinical and research settings. Both HADS-D and HADS-T have only modest
436 screening ability and discussion of their exact indications for use and related caveats are beyond
437 the scope of this article. However, there were no substantive differences in performance between
438 the HADS-D and HADS-T in detecting major depression among medical outpatients, although
439 there was a slight advantage in specificity of indeterminate equivalency for the HADS-T among
440 medical inpatients, for whom adding the anxiety items of HADS-A may improve accuracy.

441

442 **Ethical Approval:** As this study involved secondary analysis of anonymized previously
443 collected data, the Research Ethics Committee of the Jewish General Hospital declared that this
444 project did not require research ethics approval. However, for each included dataset, we
445 confirmed that the original study received ethics approval and that all patients provided informed
446 consent.

447 **REFERENCES**

- 448 *Akechi, T., Okuyama, T., Sugawara, Y., Shima, Y., Furukawa, T. A., & Uchitomi, Y. (2006).
449 Screening for depression in terminally ill cancer patients in Japan. *Journal of Pain &*
450 *Symptom Management* , 31(1), 5-12.
- 451 *Al-Asmi, A., Dorvlo, A. S., Burke, D. T., Al-Adawi, S., Al-Zaabi, A., Al-Zadjali, H. A., ... &
452 Al-Adawi, S. (2012). The detection of mood and anxiety in people with epilepsy using
453 two-phase designs: experiences from a tertiary care centre in Oman. *Epilepsy Research*,
454 98(2-3), 174–181.
- 455 American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders:
456 DSM-III. 3rd ed. Washington, DC: American Psychiatric Association.
- 457 American Psychiatric Association. (1994) Diagnostic and statistical manual of mental disorders:
458 DSM-IV. 4th ed. Washington (DC): American Psychiatric Association.
- 459 American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders:
460 DSM-IV-TR. 4th ed, Text Revision. Washington (DC): American Psychiatric
461 Association.
- 462 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders:
463 DSM-5. 5th ed. Washington (DC): American Psychiatric Association.
- 464 *Amoozegar, F., Patten, S. B., Becker, W. J., Bulloch, A. G., Fiest, K. M., Davenport, W. J., ...
465 & Jette, N. (2017). The prevalence of depression and the accuracy of depression
466 screening tools in migraine patients. *General Hospital Psychiatry*, 48, 25-31.
- 467 Bates, D., Maechler, M., Bolker, B. M., & Walker, S. C. (2015). Fitting Linear Mixed-Effects
468 Models Using lme4. *Journal of Statistical Software*, 67(1), 1-48.
469 doi:10.18637/jss.v067.i01

470 *Bayón-Pérez, C., Hernando, A., Álvarez-Comino, M., Cebolla, S., Serrano, L., Gutiérrez, F., ...
471 & Pulido, F. (2016). Toward a comprehensive care of HIV patients: finding a strategy to
472 detect depression in a Spanish HIV cohort. *AIDS Care*, 28, 834 - 841.

473 *Beck, K. R., Tan, S. M., Lum, S. S., Lim, L. E., & Krishna, L. K. (2016). Validation of the
474 emotion thermometers and hospital anxiety and depression scales in Singapore:
475 Screening cancer patients for distress, anxiety and depression. *Asia-Pacific Journal of*
476 *Clinical Oncology*, 12(2), e241–e249.

477 *Beraldi, A., Baklayan, A., Hoster, E., Hiddemann, W., & Heussner, P. (2014). Which
478 questionnaire is most suitable for the detection of depressive disorders in haemato-
479 oncological patients? Comparison between HADS, CES-D and PHQ-9. *Oncology*
480 *Research and Treatment*, 37,108.

481 *Bernstein, C. N., Zhang, L., Lix, L. M., Graff, L. A., Walker, J. R., Fisk, J. D., ... & CIHR
482 Team in Defining the Burden and Managing the Effects of Immune-mediated
483 Inflammatory Disease. (2018). The validity and reliability of screening measures for
484 depression and anxiety disorders in inflammatory bowel disease. *Inflammatory Bowel*
485 *Diseases*, 24(9), 1867-1875.

486 *Braeken, A. P. B. M., Lechner, L., Houben, R. M. A., Van Gils, F. C. J. M., & Kempen, G. I. J.
487 M. (2011). Psychometric properties of the Screening Inventory of Psychosocial Problems
488 (SIPP) in Dutch cancer patients treated with radiotherapy. *European Journal of Cancer*
489 *Care*, 20(3), 305-314.

490 Brugha, T. S., Bebbington, P. E., & Jenkins, R. (1999). A difference that matters: comparisons of
491 structured and semi-structured psychiatric diagnostic interviews in the general

492 population. *Psychological Medicine*, 29(5), 1013-1020.
493 doi:10.1017/S0033291799008880

494 Brugha, T. S., Jenkins, R., Taub, N., Meltzer, H., & Bebbington, P. E. (2001). A general
495 population comparison of the Composite International Diagnostic Interview (CIDI) and
496 the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). *Psychological
497 Medicine*, 31(6), 1001-1013. doi:10.1017/S0033291701004184

498 *Bunevicius, A., Peceliuniene, J., Mickuviene, N., Valius, L., & Bunevicius, R. (2007).
499 Screening for depression and anxiety disorders in primary care patients. *Depression and
500 Anxiety*, 24(7), 455–460.

501 *Bunevicius, A., Staniute, M., Brozaitiene, J., & Bunevicius, R. (2012). Diagnostic accuracy of
502 self-rating scales for screening of depression in coronary artery disease patients. *Journal
503 of Psychosomatic Research*, 72(1), 22–25.

504 *Butnorienė, J., Bunevicius, A., Norkus, A., & Bunevicius, R. (2014). Depression but not
505 anxiety is associated with metabolic syndrome in primary care based community sample.
506 *Psychoneuroendocrinology*, 40, 269–276.

507 *Can, C., Cimilli, C., Ozenli, Y., Ergor, G., Aysevener, E. O., Unek, T., & Astarcioglu, I. (2018).
508 Quality of life and psychiatric disorders before and one year after liver
509 transplantation. *Journal of Clinical and Analytical Medicine*, 9(5), 396-401.

510 *Chen, C. K., Tsai, Y. C., Hsu, H. J., Wu, I. W., Sun, C. Y., Chou, C. C., ... & Wang, L. J.
511 (2010). Depression and suicide risk in hemodialysis patients with chronic renal failure.
512 *Psychosomatics*, 51(6), 528–528.e6.

513 *Cheung, G., Patrick, C., Sullivan, G., Cooray, M., & Chang, C. L. (2012). Sensitivity and
514 specificity of the Geriatric Anxiety Inventory and the Hospital Anxiety and Depression

515 Scale in the detection of anxiety disorders in older people with chronic obstructive
516 pulmonary disease. *International Psychogeriatrics*, 24(1), 128–136.

517 Clarke, D. M., Smith, G. C., Herrman, H. E., & McKenzie, D. P. (1998). Monash Interview for
518 Liaison Psychiatry (MILP) - Development, reliability, and procedural validity.
519 *Psychosomatics*, 39(4), 318-328. doi:10.1016/S0033-3182(98)71320-9

520 *Consoli, S. M., Rolhion, S., Martin, C., Ruel, K., Cambazard, F., Pellet, J., & Misery, L. (2006).
521 Low levels of emotional awareness predict a better response to dermatological treatment
522 in patients with psoriasis. *Dermatology*, 212(2), 128–136.

523 *Costa-Requena, G., Ballester Arnal, R., & Gil, F. (2013). Perceived social support in Spanish
524 cancer outpatients with psychiatric disorder. *Stress and Health: Journal of the*
525 *International Society for the Investigation of Stress*, 29(5), 421–426.

526 *Cukor, D., Coplan, J., Brown, C., Friedman, S., Newville, H., Safier, M., ... & Kimmel, P. L.
527 (2008). Anxiety disorders in adults treated by hemodialysis: a single-center
528 study. *American Journal of Kidney Diseases*, 52(1), 128-136.

529 *da Rocha e Silva, C. E. D. R., Brasil, M. A. A., Do Nascimento, E. M., de Bragança Pereira, B.,
530 & André, C. (2013). Is poststroke depression a major depression?. *Cerebrovascular*
531 *Diseases*, 35(4), 385-391.

532 *De Souza, J., Jones, L. A., & Rickards, H. (2010). Validation of self-report depression rating
533 scales in Huntington's disease. *Movement Disorders*, 25(1), 91-96.

534 *de la Torre, A. Y., Oliva, N., Echevarrieta, P. L., Pérez, B. G., Caporusso, G. B., Titaro, A.
535 J., ... & Daray, F. M. (2016). Major depression in hospitalized Argentine general medical
536 patients: Prevalence and risk factors. *Journal of Affective Disorders*, 197, 36–42.

537 *de Oliveira, G. N., Lessa, J. M., Gonçalves, A. P., Portela, E. J., Sander, J. W., & Teixeira, A.
538 L. (2014). Screening for depression in people with epilepsy: comparative study among
539 neurological disorders depression inventory for epilepsy (NDDI-E), hospital anxiety and
540 depression scale depression subscale (HADS-D), and Beck depression inventory (BDI).
541 *Epilepsy & Behavior, 34*, 50–54.

542 *Douven, E., Schievink, S. H., Verhey, F. R., van Oostenbrugge, R. J., Aalten, P., Staals, J., &
543 Köhler, S. (2016). The Cognition and Affect after Stroke - a Prospective Evaluation of
544 Risks (CASPER) study: rationale and design. *BMC Neurology, 16*, 65.

545 *Dorow, M., Stein, J., Pabst, A., Weyerer, S., Werle, J., Maier, W., ... & Riedel-Heller, S. G.
546 (2018). Categorical and dimensional perspectives on depression in elderly primary care
547 patients—Results of the AgeMooDe study. *International Journal of Methods in*
548 *Psychiatric Research, 27*(1), e1577.

549 *Drabe, N., Zwahlen, D., Büchi, S., Moergeli, H., Zwahlen, R. A., & Jenewein, J. (2008).
550 Psychiatric morbidity and quality of life in wives of men with long-term head and neck
551 cancer. *Psycho-Oncology, 17*(2), 199–204.

552 Endicott, J., & Spitzer, R. L. (1987). [Schedule for Affective Disorders and Schizophrenia
553 (SADS)]. *Acta psychiatrica Belgica, 87*(4), 361-516.

554 *Fábregas, B. C., Moura, A. S., Ávila, R. E., Faria, M. N., Carmo, R. A., & Teixeira, A. L.
555 (2014). Sexual dysfunction and dissatisfaction in chronic hepatitis C patients. *Revista da*
556 *Sociedade Brasileira de Medicina Tropical, 47*(5), 564–572.

557 Fagerland, M. W., Lydersen, S., & Laake, P. (2014). Recommended tests and confidence
558 intervals for paired binomial proportions. *Statistics in Medicine, 33*(16), 2850-2875.
559 doi:10.1002/sim.6148

560 *Ferentinos, P., Paparrigopoulos, T., Rentzos, M., Zouvelou, V., Alexakis, T., & Evdokimidis, I.
561 (2011). Prevalence of major depression in ALS: comparison of a semi-structured
562 interview and four self-report measures. *Amyotrophic Lateral Sclerosis*, 12(4), 297-302..

563 *Fiest, K. M., Patten, S. B., Wiebe, S., Bulloch, A. G., Maxwell, C. J., Jette, N. (2014).
564 Validating screening tools for depression in epilepsy. *Epilepsia*, 55(10), 1642-1650.

565 First, M. B. (1995). *Structured Clinical Interview for the DSM (SCID)*. New York (NY): John
566 Wiley & Sons, Inc.

567 *Fischer, H. F., Klug, C., Roeper, K., Blozik, E., Edelmann, F., Eisele, M., ... & Herrmann-
568 Lingen, C. (2014). Screening for mental disorders in heart failure patients using
569 computer-adaptive tests. *Quality of Life Research*, 23(5), 1609–1618.

570 *Gagnon, N., Flint, A. J., Naglie, G., & Devins, G. M. (2005). Affective correlates of fear of
571 falling in elderly persons. *The American Journal of Geriatric Psychiatry*, 13(1), 7–14.

572 *Gandy, M., Sharpe, L., Perry, K. N., Miller, L., Thayer, Z., Boserio, J., & Mohamed, A. (2012).
573 Assessing the efficacy of 2 screening measures for depression in people with epilepsy.
574 *Neurology*, 79(4), 371–375.

575 *Golden, J., Conroy, R. M., & O'Dwyer, A. M. (2007). Reliability and validity of the Hospital
576 Anxiety and Depression Scale and the Beck Depression Inventory (Full and FastScreen
577 scales) in detecting depression in persons with hepatitis C. *Journal of Affective Disorders*,
578 100(1-3), 265–269.

579 *Gould, K. R., Ponsford, J. L., Johnston, L., & Schönberger, M. (2011). Predictive and
580 associated factors of psychiatric disorders after traumatic brain injury: a prospective
581 study. *Journal of Neurotrauma*, 28(7), 1155–1163.

582 *Grassi, L., Sabato, S., Rossi, E., Marmai, L., & Biancosino, B. (2009). Affective syndromes and
583 their screening in cancer patients with early and stable disease: Italian ICD-10 data and
584 performance of the Distress Thermometer from the Southern European Psycho-Oncology
585 Study (SEPOS). *Journal of Affective Disorders, 114*(1-3), 193–199.

586 *Hahn, D., Reuter, K., & Härter, M. (2006). Screening for affective and anxiety disorders in
587 medical patients - comparison of HADS, GHQ-12 and Brief-PHQ. *GMS Psycho-Social*
588 *Medicine, 3*.

589 Harel, D., Levis, B., Ishihara, M., Levis, A. W., Vigod, S. N., Howard, L. M., . . . DEPRESSion
590 Screening Data (DEPRESSD) EPDS Collaboration. (2021). Shortening the Edinburgh
591 postnatal depression scale using optimal test assembly methods: Development of the
592 EPDS-Dep-5. *Acta Psychiatrica Scandinavica, 143*(4), 348-362. doi:10.1111/acps.13272

593 *Härter, M., Woll, S., Wunsch, A., Bengel, J., & Reuter, K. (2005). Screening for mental
594 disorders in cancer, cardiovascular and musculoskeletal diseases. *Social Psychiatry and*
595 *Psychiatric Epidemiology, 41*, 56-62.

596 *Hartung, T. J., Friedrich, M., Johansen, C., Wittchen, H. U., Faller, H., Koch, U., Brähler,
597 E., ... & Mehnert, A. (2017). The Hospital Anxiety and Depression Scale (HADS) and
598 the 9-item Patient Health Questionnaire (PHQ-9) as screening instruments for depression
599 in patients with cancer. *Cancer, 123*(21), 4236–4243.

600 Higgins, J. P. T., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis.
601 *Statistics In Medicine, 21*(11), 1539-1558. doi:10.1002/sim.1186

602 *Hitchon, C. A., Zhang, L., Peschken, C. A., Lix, L. M., Graff, L. A., Fisk, J. D., Patten, S. B.,
603 Bolton, J., Sareen, J., El-Gabalawy, R., Marriott, J., Bernstein, C. N., & Marrie, R. A.

604 (2020). Validity and Reliability of Screening Measures for Depression and Anxiety
605 Disorders in Rheumatoid Arthritis. *Arthritis Care & Research*, 72(8), 1130–1139.

606 *Honarmand, K., & Feinstein, A. (2009). Validation of the Hospital Anxiety and Depression
607 Scale for use with multiple sclerosis patients. *Multiple Sclerosis*, 15(12), 1518–1524.

608 *Huey, N. S., Guan, N. C., Gill, J. S., Hui, K. O., Sulaiman, A. H., & Kunagasundram, S. (2018).
609 Core Symptoms of Major Depressive Disorder among Palliative Care Patients.
610 *International Journal of Environmental Research and Public Health*, 15(8), 1758.

611 Ishihara, M., Harel, D., Levis, B., Levis, A. W., Riehm, K. E., Saadat, N., . . . Thombs, B. D.
612 (2019). Shortening self-report mental health symptom measures through optimal test
613 assembly methods: Development and validation of the Patient Health Questionnaire-
614 Depression-4. *Depression and Anxiety*, 36(1), 82-92. doi:10.1002/da.22841

615 *Jackson, M. L., Tolson, J., Schembri, R., Bartlett, D., Rayner, G., Lee, V. V., & Barnes, M.
616 (2021). Does continuous positive airways pressure treatment improve clinical depression
617 in obstructive sleep apnea? A randomized wait-list controlled study. *Depression and*
618 *Anxiety*, 38(5), 498–507.

619 *Jang, J. E., Kim, S. W., Kim, S. Y., Kim, J. M., Park, M. H., Yoon, J. H., . . . & Yoon, J. S.
620 (2013). Religiosity, depression, and quality of life in Korean patients with breast cancer:
621 a 1-year prospective longitudinal study. *Psycho-Oncology*, 22(4), 922–929.

622 Joffres, M., Jaramillo, A., Dickinson, J., Lewin, G., Pottie, K., Shaw, E., Gorber, S. C., &
623 Tonelli, M. (2013). Recommendations on screening for depression in adults. *CMAJ* :
624 *Canadian Medical Association Journal*, 185(9), 775–782.
625 <https://doi.org/10.1503/cmaj.130403>

626 *Juliao, M., Barbosa, A., Oliveira, F., & Nunes, B. (2013). Prevalence and factors associated
627 with desire for death in patients with advanced disease: results from a Portuguese cross-
628 sectional study. *Psychosomatics*, 54(5), 451–457.

629 *Kang, H. J., Stewart, R., Kim, J. M., Jang, J. E., Kim, S. Y., Bae, K. Y., ... & Yoon, J. S.
630 (2013). Comparative validity of depression assessment scales for screening poststroke
631 depression. *Journal of Affective Disorders*, 147(1-3), 186–191.

632 *Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., ... & Lehnert, T.
633 (2004). Recognition of distress and psychiatric morbidity in cancer patients: a multi-
634 method approach. *Annals of Oncology*, 15(8),1243.

635 *Kjaergaard, M., Arfwedson Wang, C. E., Waterloo, K., & Jorde, R. (2014). A study of the
636 psychometric properties of the Beck Depression Inventory-II, the Montgomery and
637 Åsberg Depression Rating Scale, and the Hospital Anxiety and Depression Scale in a
638 sample from a healthy population. *Scandinavian Journal of Psychology*, 55(1), 83–89.

639 *Kugaya, A., Akechi, T., Okuyama, T., Nakano, T., Mikami, I., Okamura, H., & Uchitomi, Y.
640 (2000). Prevalence, predictive factors, and screening for psychologic distress in patients
641 with newly diagnosed head and neck cancer. *Cancer*, 88(12), 2817–2823.

642 *Lambert, S. D., Clover, K., Pallant, J. F., Britton, B., King, M. T., Mitchell, A. J., Carter, G.
643 (2015). Making Sense of Variations in Prevalence Estimates of Depression in Cancer: A
644 Co-Calibration of Commonly Used Depression Scales Using Rasch Analysis. *Journal of*
645 *the National Comprehensive Cancer Network*, 13(10),1203.

646 *Law, M., Naughton, M. T., Dhar, A., Barton, D., & Dabscheck, E. (2014). Validation of two
647 depression screening instruments in a sleep disorders clinic. *Journal of Clinical Sleep*
648 *Medicine*, 10(6), 683–688.

649 Lecrubier, Y., Sheehan, D. V., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., . . . Dunbar,
650 G. C. (1997). The Mini International Neuropsychiatric Interview (MINI). A short
651 diagnostic structured interview: Reliability and validity according to the CIDI. *European*
652 *Psychiatry*, *12*(5), 224-231. doi:10.1016/S0924-9338(97)83296-8

653 *Lee, Y., Wu, Y. S., Chien, C. Y., Fang, F. M., & Hung, C. F. (2016). Use of the Hospital
654 Anxiety and Depression Scale and the Taiwanese Depression Questionnaire for screening
655 depression in head and neck cancer patients in Taiwan. *Neuropsychiatric Disease and*
656 *Treatment*, *12*, 2649–2657.

657 *Lee, C. Y., Lee, Y., Wang, L. J., Chien, C. Y., Fang, F. M., & Lin, P. Y. (2017). Depression,
658 anxiety, quality of life, and predictors of depressive disorders in caregivers of patients
659 with head and neck cancer: A six-month follow-up study. *Journal of Psychosomatic*
660 *Research*, *100*, 29–34.

661 *Lees, R.A., Stott, D.J., Quinn, T.J., & Broomfield, N.M. (2014). Feasibility and Diagnostic
662 Accuracy of Early Mood Screening to Diagnose Persisting Clinical Depression/Anxiety
663 Disorder after Stroke. *Cerebrovascular Diseases*, *37*, 323 - 329.

664 Levis, B., Benedetti, A., Levis, A. W., Ioannidis, J. P. A., Shrier, I., Cuijpers, P., . . . Thombs, B.
665 D. (2017). Selective Cutoff Reporting in Studies of Diagnostic Test Accuracy: A
666 Comparison of Conventional and Individual-Patient-Data Meta-Analyses of the Patient
667 Health Questionnaire-9 Depression Screening Tool. *American Journal of Epidemiology*,
668 *185*(10), 954-964. doi:10.1093/aje/kww191

669 Levis, B., Benedetti, A., Riehm, K. E., Saadat, N., Levis, A. W., Azar, M., . . . Thombs, B. D.
670 (2018). Probability of major depression diagnostic classification using semi-structured

671 versus fully structured diagnostic interviews. *British Journal of Psychiatry*, 212(6), 377-
672 385. doi:10.1192/bjp.2018.54

673 Levis, B., Benedetti, A., Thombs, B. D., Akena, D. H., Arroll, B., Ayalon, L., . . . DEPRESSion
674 Screening Data (DEPRESSD) Collaboration. (2019). Accuracy of Patient Health
675 Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant
676 data meta-analysis. *BMJ*, 365. doi:10.1136/bmj.l1476

677 Levis, B., McMillan, D., Sun, Y., He, C., Rice, D. B., Krishnan, A., . . . Thombs, B. D. (2019).
678 Comparison of major depression diagnostic classification probability using the SCID,
679 CIDI, and MINI diagnostic interviews among women in pregnancy or postpartum: An
680 individual participant data meta-analysis. *International Journal of Methods in Psychiatric
681 Research*, 28(4). doi:10.1002/mpr.1803

682 Levis, B., Negeri, Z., Sun, Y., Benedetti, A., Thombs, B. D., & DEPRESSion Screening Data
683 (DEPRESSD) EPDS Group. (2020). Accuracy of the Edinburgh Postnatal Depression
684 Scale (EPDS) for screening to detect major depression among pregnant and postpartum
685 women: systematic review and meta-analysis of individual participant data. *BMJ*, 371.
686 doi:10.1136/bmj.m4022

687 *Loosman, W. L., Siegert, C. E., Korzec, A., & Honig, A. (2010). Validity of the Hospital
688 Anxiety and Depression Scale and the Beck Depression Inventory for use in end-stage
689 renal disease patients. *The British Journal of Clinical Psychology*, 49(Pt 4), 507–516.

690 *Love, A. W., Kissane, D. W., Bloch, S., & Clarke, D. (2002). Diagnostic efficiency of the
691 Hospital Anxiety and Depression Scale in women with early stage breast cancer. *The
692 Australian and New Zealand Journal of Psychiatry*, 36(2), 246–250.

- 693 *Love, A. W., Grabsch, B., Clarke, D. M., Bloch, S., & Kissane, D. W. (2004). Screening for
694 depression in women with metastatic breast cancer: a comparison of the Beck Depression
695 Inventory Short Form and the Hospital Anxiety and Depression Scale. *The Australian
696 and New Zealand journal of psychiatry*, 38(7), 526–531.
- 697 *Lowe, B., Gräfe, K., Zipfel, S., Spitzer, R. L., Herrmann-Lingen, C., Witte, S., & Herzog, W.
698 (2003). Detecting panic disorder in medical and psychosomatic outpatients: comparative
699 validation of the Hospital Anxiety and Depression Scale, the Patient Health
700 Questionnaire, a screening question, and physicians' diagnosis. *Journal of Psychosomatic
701 Research*, 55(6), 515–519.
- 702 *Marrie, R. A., Zhang, L., Lix, L. M., Graff, L. A., Walker, J. R., Fisk, J. D., ... & Bernstein, C.
703 N. (2018). The validity and reliability of screening measures for depression and anxiety
704 disorders in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, 20, 9–15.
- 705 *Massardo, L., Bravo-Zehnder, M., Calderón, J., Flores, P., Padilla, O., Aguirre, J. M., ... &
706 González, A. (2015). Anti-N-methyl-D-aspartate receptor and anti-ribosomal-P
707 autoantibodies contribute to cognitive dysfunction in systemic lupus erythematosus.
708 *Lupus*, 24(6), 558–568.
- 709 *Matsuoka, Y., Nishi, D., Nakajima, S., Yonemoto, N., Hashimoto, K., Noguchi, H., ... & Kim,
710 Y. (2009). The Tachikawa cohort of motor vehicle accident study investigating
711 psychological distress: Design, methods and cohort profiles. *Social Psychiatry and
712 Psychiatric Epidemiology*, 44(4), 333–340.
- 713 *McFarlane, A. C., Browne, D., Bryant, R. A., O'Donnell, M., Silove, D., Creamer, M., &
714 Horsley, K. (2009). A longitudinal analysis of alcohol consumption and the risk of
715 posttraumatic symptoms. *Journal of Affective Disorders*, 118(1-3), 166–172.

716 McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016).
717 PRESS peer review of electronic search strategies: 2015 guideline statement. *Journal of*
718 *Clinical Epidemiology*, *75*, 40-46.

719 *Meyer, A., Wollbrück, D., Täschner, R., Singer, S., Ehrensperger, C., Danker, H., ... &
720 Schwarz, R. (2008). Psychological status and morbidity of the spouses of laryngectomy
721 patients. *Zeitschrift für Klinische Psychologie und Psychotherapie: Forschung und*
722 *Praxis*, *37*, 172.

723 *Michopoulos, I., Douzenis, A., Gournellis, R., Christodoulou, C., Kalkavoura, C.,
724 Michalopoulou, P.G., ... & Lykouras, L. (2010). Major depression in elderly medical
725 inpatients in Greece, prevalence and identification. *Aging Clinical and Experimental*
726 *Research*, *22*, 148-151.

727 Mitchell, A. J., Meader, N., & Symonds, P. (2010). Diagnostic validity of the Hospital Anxiety
728 and Depression Scale (HADS) in cancer and palliative settings: A meta-analysis. *Journal*
729 *of Affective Disorders*, *126*(3), 335-348. doi:10.1016/j.jad.2010.01.067

730 National Collaborating Centre for Mental Health (UK). (2010). *Depression in Adults with a*
731 *Chronic Physical Health Problem: Treatment and Management*. British Psychological
732 Society (UK). <http://www.ncbi.nlm.nih.gov/books/NBK82916/>

733 NCSS. (2017). One ROC curve and cutoff analysis, Chapter 546. Retrieved September 20, 2021,
734 from <https://www.ncss.com/software/ncss/roc-curves-ncss/>

735 Negeri, Z. F., Levis, B., Sun, Y., He, C., Krishnan, A., Wu, Y., Thombs, B. D. . . . DEPRESSion
736 Screening Data (DEPRESSD) PHQ Group. (2021). Accuracy of the Patient Health
737 Questionnaire-9 (PHQ-9) for screening to detect major depression: an updated systematic

738 review and individual participant data meta-analysis. *BMJ*, 375:n2183. doi:
739 <https://doi.org/10.1136/bmj.n2183>

740 Neupane, D., Levis, B., Bhandari, P. M., Thombs, B. D., Benedetti, A., & DEPRESSion
741 Screening Data (DEPRESSD) Collaboration. (2021). Selective cutoff reporting in studies
742 of the accuracy of the PHQ-9 and EPDS depressions screening tools: comparison of
743 results based on published cutoffs versus all cutoffs using individual participant data
744 meta-analysis. *International Journal of Epidemiology*, 30(3), e1873. doi:
745 10.1002/mpr.1873.

746 Nosen, E., & Woody, S. R. (2008). Chapter 8: Diagnostic assessment in research. In *Handbook*
747 *of Research Methods in Abnormal and Clinical Psychology* (ed. D. McKay), pp. 109-124.
748 Sage: Thousand Oaks.

749 *O'Rourke, S., MacHale, S., Signorini, D., Dennis, M. (1998). Detecting psychiatric morbidity
750 after stroke: comparison of the GHQ and the HAD Scale. *Stroke*, 29, 980-985.

751 *Öztürk, A., Deveci, E., Bağcıoğlu, E., Atalay, F. & Serdar, Z. (2013). Anxiety, depression,
752 social phobia, and quality of life in Turkish patients with acne and their relationships with
753 the severity of acne. *Turkish Journal of Medical Sciences*, 43 (4), 660-666.

754 *Patel, D., Sharpe, L., Thewes, B., Rickard, J., Schnieden, V., & Lewis, C. (2010). Feasibility of
755 using risk factors to screen for psychological disorder during routine breast care nurse
756 consultations. *Cancer Nursing*, 33(1), 19–27.

757 *Patel, D., Sharpe, L.A., Thewes, B., Bell, M.L., & Clarke, S.J. (2011). Using the Distress
758 Thermometer and Hospital Anxiety and Depression Scale to screen for psychosocial
759 morbidity in patients diagnosed with colorectal cancer. *Journal of Affective Disorders*,
760 131(1-3), 412-6.

761 *Patten, S. B., Burton, J. M., Fiest, K. M., Wiebe, S., Bulloch, A. G., Koch, M., ... & Jetté, N.
762 (2015). Validity of four screening scales for major depression in MS. *Multiple Sclerosis*,
763 21(8), 1064–1071.

764 *Pedroso, V. S., Vieira, É. L., Brunoni, A. R., Lauterbach, E. C., Teixeira, A. L. (2016).
765 Psychopathological evaluation and use of the Hospital Anxiety and Depression Scale in a
766 sample of Brazilian patients with post-stroke depression. *Archives of Clinical Psychiatry*
767 (São Paulo), 43, 147-50.

768 *Phan, T., Carter, O., Adams, C., Waterer, G., Chung, L. P., Hawkins, M., ... & Strobel, N.
769 (2016). Discriminant validity of the Hospital Anxiety and Depression Scale, Beck
770 Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of
771 depression and anxiety in patients with chronic obstructive pulmonary disease. *Chronic*
772 *Respiratory Disease*, 13(3), 220–228.

773 *Pintor, L., Fuente, E.D., Peri, J.M., Pérez-Villa, F., & Roig, E. (2006). Evaluación psiquiátrica
774 transversal en pacientes candidatos a un trasplante cardíaco. *Psiquiatría Biológica*, 13,
775 122-126.

776 *Prisnie, J. C., Fiest, K. M., Coutts, S. B., Patten, S. B., Atta, C. A., Blaikie, L., ... & Jetté, N.
777 (2016). Validating screening tools for depression in stroke and transient ischemic attack
778 patients. *International Journal of Psychiatry in Medicine*, 51(3), 262–277.

779 R Core Team. (2020). R: A language and environment for statistical computing. R Foundation
780 for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.

781 RStudio Team. (2020). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA
782 <http://www.rstudio.com/>.

783 *Reme, S. E., Lie, S. A., & Eriksen, H. R. (2014). Are 2 questions enough to screen for
784 depression and anxiety in patients with chronic low back pain?. *Spine*, *39*(7), E455–E462.

785 Rice, D. B., & Thombs, B. D. (2016). Risk of Bias from Inclusion of Currently Diagnosed or
786 Treated Patients in Studies of Depression Screening Tool Accuracy: A Cross-Sectional
787 Analysis of Recently Published Primary Studies and Meta-Analyses. *Plos One*, *11*(2).
788 doi:10.1371/journal.pone.0150067

789 Riley, R. D., Dodd, S. R., Craig, J. V., Thompson, J. R., & Williamson, P. R. (2008). Meta-
790 analysis of diagnostic test studies using individual patient data and aggregate data.
791 *Statistics in Medicine*, *27*(29), 6111-6136. doi:10.1002/sim.3441

792 Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010). Meta-analysis of individual participant
793 data: rationale, conduct, and reporting. *BMJ*, *340*. doi:10.1136/bmj.c221

794 Robins, L. N., Wing, J., Wittchen, H. U., Helzer, J. E., Babor, T. F., Burke, J., . . . Towle, L. H.
795 (1988). The Composite International Diagnostic Interview: an epidemiologic instrument
796 suitable for use in conjunction with different diagnostic systems and in different cultures.
797 *Archives Of General Psychiatry*, *45*(12), 1069-1077.

798 *Rooney, A. G., McNamara, S., Mackinnon, M., Fraser, M., Rampling, R., Carson, A., & Grant,
799 R. (2013). Screening for major depressive disorder in adults with cerebral glioma: an
800 initial validation of 3 self-report instruments. *Neuro-Oncology*, *15*(1), 122-129.

801 *Ryan, D. A., Gallagher, P., Wright, S., Cassidy, E. M. (2012). Sensitivity and specificity of the
802 Distress Thermometer and a two-item depression screen (Patient Health Questionnaire-2)
803 with a 'help' question for psychological distress and psychiatric morbidity in patients with
804 advanced cancer. *Psycho-Oncology*, *21*(12), 1275.

805 *Sanchez-Gistau, V., Sugranyes, G., Baillés, E., Carreño, M., Donaire, A., Bargalló, N., &
806 Pintor, L. (2012). Is major depressive disorder specifically associated with mesial
807 temporal sclerosis?. *Epilepsia*, 53(2), 386–392.

808 *Sánchez, R., Peri, J. M., Baillés, E., Bastidas, A., Pérez-Villa, F., Bulbena, A., & Pintor, L.
809 (2012). Evaluación de psicopatología, afrontamiento y apoyo familiar en el cumplimiento
810 de pautas médicas en los 12 meses posteriores a un trasplante cardiaco. *Psiquiatría*
811 *Biológica*, 19, 1-5.

812 *Sánchez, R., Baillés, E., Peri, J.M., Bastidas, A., Pérez-Villa, F., Bulbena, A., & Pintor, L.
813 (2014). Cross-sectional psychosocial evaluation of heart transplantation candidates.
814 *General Hospital Psychiatry*, 36(6), 680-5.

815 *Saracino, R.M., Weinberger, M.I., Roth, A.J., Hurria, A., & Nelson, C.J. (2017). Assessing
816 depression in a geriatric cancer population. *Psycho-Oncology*, 26, 1484 - 1490.

817 Schatzberg, A. F. (2019). Scientific Issues Relevant to Improving the Diagnosis, Risk
818 Assessment, and Treatment of Major Depression. *American Journal of Psychiatry*,
819 176(5), 342-347. doi:10.1176/appi.ajp.2019.19030273

820 *Schellekens, M.P., van den Hurk, D.G., Prins, J.B., Molema, J., van der Drift, M.A., &
821 Speckens, A.E. (2016). The suitability of the Hospital Anxiety and Depression Scale,
822 Distress Thermometer and other instruments to screen for psychiatric disorders in both
823 lung cancer patients and their partners. *Journal of Affective Disorders*, 203, 176-183 .

824 *Schwarzbold, M.L., Diaz, A.P., Nunes, J.C., Sousa, D.S., Hohl, A., Guarnieri, R., ... & Walz,
825 R. (2014). Validity and screening properties of three depression rating scales in a
826 prospective sample of patients with severe traumatic brain injury. *Revista brasileira de*
827 *psiquiatria*, 36, 206-12 .

828 *Senturk, V., Stewart, R.J., & Sağduyu, A. (2007). Screening for mental disorders in leprosy
829 patients: comparing the internal consistency and screening properties of HADS and
830 GHQ-12. *Leprosy Review*, 78(3), 231-42 .

831 Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Janavs, J., Weiller, E., Keskiner, A., . . . Dunbar,
832 G. C. (1997). The validity of the Mini International Neuropsychiatric Interview (MINI)
833 according to the SCID-P and its reliability. *European Psychiatry*, 12(5), 232-241.
834 doi:10.1016/S0924-9338(97)83297-X

835 *Sia, A.D., Williams, L.J., Pasco, J.A., Jacka, F.N., Brennan-Olsen, S.L., & Veerman, J.L.
836 (2018). The Population Mean Mood Predicts The Prevalence of Depression in an
837 Australian Context. *Australian & New Zealand Journal of Psychiatry*, 52, 461 - 472.

838 *Simard, S., & Savard, J. (2015). Screening and comorbidity of clinical levels of fear of cancer
839 recurrence. *Journal of Cancer Survivorship*, 9, 481-491.

840 *Singer, S., Danker, H., Dietz, A., Hornemann, B., Koscielny, S., Oeken, J., ... & Krauss, O.
841 (2008). Screening for mental disorders in laryngeal cancer patients: a comparison of 6
842 methods. *Psycho-Oncology*, 17.

843 *Singer, S., Kuhnt, S., Götze, H., Hauss, J., Hinz, A., Liebmann, A., Krauss, O., Lehmann, A., &
844 Schwarz, R. (2009). Hospital anxiety and depression scale cutoff scores for cancer
845 patients in acute care. *British Journal of Cancer*, 100(6), 908–912.

846 Siu, A. L., & US Preventive Services Task Force (USPSTF). (2016). Screening for Depression in
847 Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*, 315(4),
848 380–387. <https://doi.org/10.1001/jama.2015.18392>

849 *Soyseth, T. S., Lund, M. B., Bjortuft, O., Heldal, A., Søyseth, V., Dew, M. A., ... & Malt, U. F.
850 (2016). Psychiatric disorders and psychological distress in patients undergoing evaluation
851 for lung transplantation: a national cohort study. *General Hospital Psychiatry*, 42, 67–73.

852 *Stafford, L., Berk, M., & Jackson, H. J. (2007). Validity of the Hospital Anxiety and
853 Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients
854 with coronary artery disease. *General Hospital Psychiatry*, 29(5), 417–424.

855 *Stafford, L., Judd, F., Gibson, P., Komiti, A., Quinn, M., & Mann, G. B. (2014). Comparison of
856 the hospital anxiety and depression scale and the center for epidemiological studies
857 depression scale for detecting depression in women with breast or gynecologic cancer.
858 *General Hospital Psychiatry*, 36(1), 74–80.

859 *Stone, J., Townend, E., Kwan, J., Haga, K., Dennis, M. S., & Sharpe, M. (2004). Personality
860 change after stroke: Some preliminary observations. *Journal of Neurology, Neurosurgery*
861 *& Psychiatry*, 75(12), 1708–1713.

862 *Sultan, S., Luminet, O., & Hartemann, A. (2010). Cognitive and anxiety symptoms in screening
863 for clinical depression in diabetes: a systematic examination of diagnostic performances
864 of the HADS and BDI-SF. *Journal of Affective Disorders*, 123(1-3), 332–336.

865 Thombs, B. D., Arthurs, E., El-Baalbaki, G., Meijer, A., Ziegelstein, R. C., & Steele, R. J.
866 (2011). Risk of bias from inclusion of patients who already have diagnosis of or are
867 undergoing treatment for depression in diagnostic accuracy studies of screening tools for
868 depression: systematic review. *BMJ*, 343. doi:10.1136/bmj.d4825

869 Thombs, B. D., Benedetti, A., Kloda, L. A., Levis, B., Azar, M., Riehm, K. E., . . . Tonelli, M.
870 (2016). Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and
871 Depression Scale (HADS-D) for detecting major depression: protocol for a systematic

872 review and individual patient data meta-analyses. *BMJ Open*, 6(4). doi:10.1136/bmjopen-
873 2016-011913

874 Thombs, B. D., & Rice, D. B. (2016). Sample sizes and precision of estimates of sensitivity and
875 specificity from primary studies on the diagnostic accuracy of depression screening tools:
876 a survey of recently published studies. *International Journal of Methods in Psychiatric
877 Research*, 25(2), 145-152. doi:10.1002/mpr.1504

878 *Tiringer, I., Simon, A., Herrfurth, D., Suri, I., Szalai, K., & Veress, A. (2008). Occurrence of
879 anxiety and depression disorders after acute cardiac events during hospital rehabilitation.
880 Application of the Hospital Anxiety and Depression Scale as a screening instrument.
881 *Psychiatria Hungarica*, 23(6), 430–443.

882 *Tung, K. Y., Cheng, K. S., Lee, W. K., Kwong, P. K., Chan, K. W., Law, A. C., & Lo, W. T.
883 (2015). Psychiatric Morbidity in Chinese Adults with Type 1 Diabetes in Hong Kong.
884 *East Asian Archives of Psychiatry*, 25(3), 128–136.

885 *Turner, A., Hambridge, J., White, J., Carter, G., Clover, K., Nelson, L., & Hackett, M. (2012).
886 Depression screening in stroke: a comparison of alternative measures with the structured
887 diagnostic interview for the diagnostic and statistical manual of mental disorders, fourth
888 edition (major depressive episode) as criterion standard. *Stroke*, 43(4), 1000–1005.

889 United Nations Development Programme. (2020). Human Development Reports.
890 <http://hdr.undp.org/en/content/human-development-index-hdi>. Accessed September 20,
891 2021.

892 van der Leeden R, Busing FMTA, Meijer E. (1997). *Bootstrap methods for two-level models*.
893 *Technical report PRM 97-04*. Leiden University, Department of Psychology: Leiden, The
894 Netherlands.

895 van der Leeden R, Meijer E, Busing FMTA (2008). Chapter 11: Resampling multilevel models.
896 In *Handbook of Multilevel Analysis* (ed. J. Leeuw, E. Meijer), pp. 401-433. Springer:
897 New York.

898 Vodermaier, A., & Millman, R. D. (2011). Accuracy of the Hospital Anxiety and Depression
899 Scale as a screening tool in cancer patients: a systematic review and meta-analysis.
900 *Supportive Care in Cancer, 19*(12), 1899-1908. doi:10.1007/s00520-011-1251-4

901 *Walker, J., Postma, K., McHugh, G. S., Rush, R., Coyle, B., Strong, V., & Sharpe, M. (2007).
902 Performance of the Hospital Anxiety and Depression Scale as a screening tool for major
903 depressive disorder in cancer patients. *Journal of Psychosomatic Research, 63*(1), 83–91.

904 *Walterfang, M. A., O'Donovan, J., Fahey, M. C., & Velakoulis, D. (2007). The neuropsychiatry
905 of adrenomyeloneuropathy. *CNS Spectrums, 12*(9), 696–701.

906 *Wong, L. Y., Yiu, R. L., Chiu, C. K., Lee, W. K., Lee, Y. L., Kwong, P. K., & Lo, W. T.
907 (2015). Prevalence of Psychiatric Morbidity in Chinese Subjects with Knee Osteoarthritis
908 in a Hong Kong Orthopaedic Clinic. *East Asian Archives of Psychiatry, 25*(4), 150–158.

909 Walker, E., & Nowacki, A. S. (2011). Understanding Equivalence and Noninferiority Testing.
910 *Journal of General Internal Medicine, 26*(2), 192-196. doi:10.1007/s11606-010-1513-8

911 Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., . . .
912 QUADAS-2 Group. (2011). QUADAS-2: A Revised Tool for the Quality Assessment of
913 Diagnostic Accuracy Studies. *Annals of Internal Medicine, 155*(8), 529-U104.
914 doi:10.7326/0003-4819-155-8-201110180-00009

915 World Health Organization (WHO). (1992). *The ICD-10 classification of mental and*
916 *behavioural disorders: clinical descriptions and diagnostic guidelines*. World Health
917 Organization.

918 World Health Organization. (1994). *Schedules for clinical assessment in neuropsychiatry:*
919 *version 2.* World Health Organization.

920 Wu, Y., Levis, B., Ioannidis, J. P. A., Benedetti, A., Thombs, B. D., & DEPRESSion Screening
921 Data (DEPRESSD) Collaboration. (2020). Probability of Major Depression Classification
922 Based on the SCID, CIDI, and MINI Diagnostic Interviews: A Synthesis of Three
923 Individual Participant Data Meta-Analyses. *Psychotherapy and Psychosomatics*, *90*(1),
924 28-40. doi:10.1159/000509283

925 Wu, Y., Levis, B., Riehm, K. E., Saadat, N., Levis, A. W., Azar, M., . . . Thombs, B. D. (2020).
926 Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review
927 and individual participant data meta-analysis. *Psychological Medicine*, *50*(8), 1368-1380.
928 doi:10.1017/S0033291719001314

929 Wu, Y., Levis, B., Sun, Y., He, C., Krishnan, A., Neupane, D., . . . DEPRESSion Screening Data
930 (DEPRESSD) HADS Group. (2021). Accuracy of the Hospital Anxiety and Depression
931 Scale Depression subscale (HADS-D) to screen for major depression: systematic review
932 and individual participant data meta-analysis. *BMJ*, *373*. doi:10.1136/bmj.n972

933 Wu, Y., Levis, B., Sun, Y., Krishnan, A., He, C., Riehm, K. E., . . . Thombs, B. D. (2020).
934 Probability of major depression diagnostic classification based on the SCID, CIDI and
935 MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale -
936 Depression subscale scores: An individual participant data meta-analysis of 73 primary
937 studies. *Journal of Psychosomatic Research*, *129*. doi:10.1016/j.jpsychores.2019.109892

938 *Yamashita, A., Noguchi, H., Hamazaki, K., Sato, Y., Narisawa, T., Kawashima, Y., . . . &
939 Matsuoka, Y. J. (2017). Serum polyunsaturated fatty acids and risk of psychiatric

940 disorder after acute coronary syndrome: A prospective cohort study. *Journal of Affective*
941 *Disorders*, 218, 306–312.

942 Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. *Acta*
943 *Psychiatrica Scandinavica*, 67(6), 361–370. [doi: 10.1111/j.1600-0447.1983.tb09716.x](https://doi.org/10.1111/j.1600-0447.1983.tb09716.x)

944

945 *Studies that included in the IPDMA

946

947




Fig 1. ROC curve for HADS-D and HADS-T across all studies.




Fig 2. Forest plots of the difference in sensitivity and specificity estimates at the optimal cutoff (HADS-D: ≥ 7 ; HADS-T: ≥ 15) between HADS-D and HADS-T across all studies^a (N Studies = 98^b; N Participants = 20,700; N major depression = 2,285)^c

^a τ^2 for the difference of sensitivity and specificity were both < 0.001 .

^b References for all included studies are marked with an asterisk in the reference list. The reference numbers refer to Supplementary Material References.

^c The studies were sorted by the sum of difference in sensitivity and difference in specificity in descending order.

Table 1. Participant data by subgroups^a

Participant Subgroup	N Studies	N Participants	N (%) Major Depression
All participants	98	20,700	2,285 (11)
Participants not currently diagnosed with a mental disorder or receiving treatment for a mental health problem	38	6,995	495 (7)
Age <60	92	11,795	1,452 (12)
Age ≥60	92	8,741	779 (9)
Women	96	11,111	1,342 (12)
Men	89	9,494	911 (10)
Very high country human development index	90	20,088	2,130 (11)
High country human development index	8	612	155 (25)
Participants diagnosed with cancer^b	27	5,767	433 (8)
Inpatient specialty care	38	8,827	1,047 (12)
Outpatient specialty care	54	9,547	1,072 (11)
Non-medical	7	1,908	116 (6)
Inpatient/outpatient mixed	3	418	50 (12)

^a Some variables were coded at the study level, while others were coded at the participant level. Thus, number of studies does not always add up to the total number.

^b The statistics here were from individual-level variable of cancer diagnosis, slight different from what we used in the subgroup analysis which based on the study-level care setting variable.

Table 2. Comparison of sensitivity and specificity estimates between HADS-D and HADS-T for pairs of optimal cutoffs and cutoffs close to the optimal cutoffs across all studies

HADS-D ^a					HADS-T					HADS-T – HADS-D			
Cutoff	Sensitivity	95% CI	Specificity	95% CI	Cutoff	Sensitivity	95% CI	Specificity	95% CI	Sensitivity	95% CI	Specificity	95% CI
5	0.90	(0.87, 0.92)	0.61	(0.58, 0.64)	11	0.91	(0.89, 0.93)	0.63	(0.60, 0.66)	0.01	(-0.01, 0.04)	0.02	(-0.00, 0.04)
6	0.86	(0.82, 0.88)	0.70	(0.67, 0.73)	13	0.86	(0.83, 0.88)	0.73	(0.70, 0.75)	0.00	(-0.03, 0.03)	0.03	(0.01, 0.05)
7 ^b	0.79	(0.75, 0.83)	0.78	(0.75, 0.80)	15 ^c	0.79	(0.76, 0.82)	0.81	(0.78, 0.83)	0.00	(-0.05, 0.02)	0.03	(0.01, 0.04)
8	0.70	(0.66, 0.74)	0.84	(0.82, 0.86)	17	0.70	(0.66, 0.74)	0.87	(0.85, 0.89)	0.00	(-0.05, 0.04)	0.03	(0.01, 0.04)
9	0.60	(0.55, 0.64)	0.89	(0.87, 0.91)	19	0.58	(0.54, 0.61)	0.91	(0.9, 0.93)	-0.02	(-0.07, 0.02)	0.02	(0.01, 0.03)
10	0.50	(0.45, 0.54)	0.92	(0.91, 0.94)	21	0.45	(0.41, 0.49)	0.95	(0.94, 0.95)	-0.05	(-0.10, -0.01)	0.03	(0.01, 0.03)
11	0.39	(0.35, 0.43)	0.95	(0.94, 0.96)	23	0.34	(0.31, 0.37)	0.97	(0.96, 0.97)	-0.05	(-0.10, -0.01)	0.02	(0.01, 0.03)

^a N Studies = 98; N Participants = 20,700; N major depression = 2,285

^b The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-D.

^c The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-T.

CI: confidence interval

Table 3. Comparison of sensitivity and specificity estimates between HADS-D and HADS-T for pairs of optimal cutoffs and cutoffs close to the optimal cutoffs across all studies via individual-level model

HADS-D^a	HADS-T	HADS-T – HADS-D	
Cutoff	Cutoff	Sensitivity	Specificity
5	11	0.02 (-0.00, 0.03)	0.01 (-0.00, 0.03)
6	13	0.01 (-0.01, 0.03)	0.03 (0.01, 0.04)
7 ^b	15 ^c	0.00 (-0.02, 0.03)	0.02 (0.01, 0.04)
8	17	0.00 (-0.03, 0.03)	0.03 (0.02, 0.04)
9	19	-0.02 (-0.05, 0.01)	0.03 (0.02, 0.04)
10	21	-0.05 (-0.08, -0.02)	0.03 (0.02, 0.03)
11	23	-0.05 (-0.09, -0.02)	0.02 (0.02, 0.03)

^a N Participants = 20,700; N major depression = 2,285

^b The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-D.

^c The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-T.

Table 4a. Comparison of sensitivity and specificity estimates between HADS-D and HADS-T for pairs of optimal cutoffs and cutoffs close to the optimal cutoffs among participants recruited from inpatient care settings

HADS-D ^a					HADS-T					HADS-T – HADS-D			
Cutoff	Sensitivity	95% CI	Specificity	95% CI	Cutoff	Sensitivity	95% CI	Specificity	95% CI	Sensitivity	95% CI	Specificity	95% CI
5	0.90	(0.87, 0.93)	0.55	(0.49, 0.60)	11	0.90	(0.87, 0.92)	0.62	(0.56, 0.68)	0.00	(-0.03, 0.03)	0.07	(0.04, 0.11)
6	0.86	(0.83, 0.89)	0.64	(0.58, 0.69)	13	0.85	(0.81, 0.88)	0.72	(0.67, 0.77)	-0.01	(-0.07, 0.02)	0.08	(0.06, 0.12)
7 ^b	0.80	(0.75, 0.83)	0.73	(0.68, 0.78)	15 ^{cd}	0.79	(0.74, 0.82)	0.81	(0.76, 0.85)	-0.01	(-0.08, 0.02)	0.08	(0.05, 0.11)
8	0.73	(0.68, 0.78)	0.80	(0.76, 0.84)	17	0.69	(0.64, 0.74)	0.87	(0.83, 0.90)	-0.04	(-0.11, 0.03)	0.07	(0.04, 0.09)
9	0.63	(0.58, 0.69)	0.86	(0.82, 0.89)	19	0.59	(0.54, 0.64)	0.91	(0.88, 0.93)	-0.04	(-0.14, 0.01)	0.05	(0.03, 0.07)
10	0.55	(0.49, 0.61)	0.90	(0.87, 0.93)	21	0.46	(0.41, 0.51)	0.95	(0.92, 0.96)	-0.09	(-0.19, -0.03)	0.05	(0.03, 0.06)
11	0.45	(0.39, 0.51)	0.93	(0.91, 0.95)	23	0.36	(0.32, 0.41)	0.97	(0.95, 0.98)	-0.09	(-0.18, -0.02)	0.04	(0.02, 0.05)

^a N Studies = 38; N Participants = 8,827; N major depression = 1,047

^b The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-D.

^c The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-T.

^d On this cutoff of HADS-T, the model convergence code was 0 when using the default optimizer in glmer, but there were meaningful CIs.

CI: confidence interval

Table 4b. Comparison of sensitivity and specificity estimates between HADS-D and HADS-T for pairs of optimal cutoffs and cutoffs close to the optimal cutoffs among participants recruited from outpatient care settings

HADS-D ^a					HADS-T					HADS-T – HADS-D			
Cutoff	Sensitivity	95% CI	Specificity	95% CI	Cutoff	Sensitivity	95% CI	Specificity	95% CI	Sensitivity	95% CI	Specificity	95% CI
5	0.91	(0.87, 0.94)	0.63	(0.60, 0.67)	11	0.92	(0.89, 0.95)	0.62	(0.59, 0.66)	0.01	(-0.02, 0.04)	-0.01	(-0.03, 0.01)
6	0.87	(0.82, 0.91)	0.72	(0.69, 0.75)	13	0.88	(0.84, 0.91)	0.72	(0.69, 0.75)	0.01	(-0.02, 0.05)	0.00	(-0.01, 0.02)
7 ^b	0.82	(0.75, 0.86)	0.79	(0.76, 0.81)	15 ^c	0.81	(0.76, 0.84)	0.80	(0.77, 0.82)	-0.01	(-0.07, 0.04)	0.01	(-0.01, 0.03)
8	0.71	(0.65, 0.77)	0.85	(0.83, 0.87)	17	0.73	(0.67, 0.78)	0.86	(0.84, 0.88)	0.02	(-0.04, 0.07)	0.01	(-0.00, 0.03)
9	0.60	(0.54, 0.66)	0.90	(0.88, 0.91)	19	0.59	(0.53, 0.65)	0.91	(0.90, 0.92)	-0.01	(-0.08, 0.04)	0.01	(0.00, 0.03)
10	0.49	(0.43, 0.55)	0.93	(0.91, 0.94)	21	0.45	(0.39, 0.52)	0.94	(0.93, 0.95)	-0.04	(-0.11, 0.02)	0.01	(0.00, 0.03)
11	0.38	(0.32, 0.44)	0.95	(0.94, 0.96)	23	0.34	(0.29, 0.39)	0.96	(0.95, 0.97)	-0.04	(-0.10, 0.01)	0.01	(0.00, 0.02)

^a N Studies = 54; N Participants = 9,547; N major depression = 1,072

^b The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-D.

^c The cutoff minimizes the values of the distance to the top-left corner of the ROC curves for HADS-T.

CI: confidence interval